Immunocore Holdings plc

NASDAQ:IMCR

Biotechnology

Healthcare
$27.51 +0.63%

+$0.18 today

Market cap
$1.42B
Beta
0.75
P/E (TTM)
-77.5
EPS (TTM)
-$0.37
52W Low $27.56High $40.72

Volume 0.30M

Average 0.40M

IMCR EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

Immunocore Holdings plcNASDAQ: IMCR

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) growth accelerates

Q1 FY2026 EPS (Basic) of $0.26 rose 160.0% year over year, ahead of the +12.9% change in trailing-twelve-month EPS (Basic).

Context

  • EPS (Basic) grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 10 analysts of $0.12 (+122.5%) for the fiscal year ending Dec 2026, a step up from the +48.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$0.26+159.1% QoQ
Last fiscal yearDec 2025
-$0.53+48.0% YoY
LTMMar 2026
-$0.37+12.9% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+160.0%+104.6%-55.4 pp
1 year+48.0%+122.5%+74.5 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

Mixed currencies · from the income statement

Latest · FY2025
(0.53) USD
Year-over-year change
+48.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How IMCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of +12.9% is the 4th highest of 11, against a peer median of -22.1%.
IMCR Competitors
EPS (Basic) for IMCR and competitors
Company Period LTM YoY 3-year CAGR
CGENCompugen Ltd.LTM Mar 2026$0.37 USD+335.9%—
IMCRImmunocore Holdings plcLTM Mar 2026-$0.37 USD+12.9%—
IMMPImmutep LimitedFY2025-A$0.42 AUD-16.7%—
IPHAInnate Pharma S.A.FY2025-€0.53 EUR+13.1%—
IBRXImmunityBio, Inc.LTM Sep 2026-$1.07 USD-167.0%—
MGNXMacroGenics, Inc.LTM Mar 2026-$1.1 USD-23.6%—
IMTXImmatics N.V.LTM Mar 2026-€1.71 EUR-1314.4%—
JANXJanux Therapeutics, Inc.LTM Mar 2026-$1.84 USD-35.3%—
XNCRXencor, Inc.LTM Jun 2026-$2.17 USD+13.5%—
RCUSArcus Biosciences, Inc.LTM Jun 2026-$3.93 USD-20.6%—
BNTXBioNTech SELTM Jun 2026-€6.73 EUR-373.9%—
Peer median (excluding IMCR) —-22.1%—

Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue27.04M144.23M197.39M247.98M297.57M
Cost of Revenue05.29M820.63K5.54M6.21M
Gross Profit27.04M138.94M196.57M242.44M291.36M
Gross Margin100.0%96.3%99.6%97.8%97.9%
Research & Development74.31M84.31M129.42M177.44M204.47M
Selling, General & Admin82.15M0114.35M121.17M120.62M
Operating Expenses156.46M181.71M243.77M298.77M325.09M
Depreciation & Amortization5.63M4.41M3.24M3.36M2.43M
EBITDA(123.58M)(38.35M)(40.87M)(38.5M)387.18K
EBITDA Margin-457.0%-26.6%-20.7%-15.5%0.1%
Operating Income(129.42M)(42.77M)(47.2M)(56.28M)(33.74M)
Operating Margin-478.5%-29.7%-23.9%-22.7%-11.3%
Interest Income65K3.76M14.23M25.62M16.48M
Interest Expense5.57M5.41M4.08M18.84M12.17M
Other Income / Expenses(3.92M)8.95M(982.07K)14.01M19.53M
Income Before Tax(133.34M)(33.82M)(48.19M)(42.32M)(14.21M)
Pre-Tax Margin-493.0%-23.4%-24.4%-17.1%-4.8%
Income Tax Expense111.19K9.65M(4.43M)(1.48M)12.21M
Net Income(133.45M)(43.46M)(43.75M)(40.81M)(26.42M)
Net Margin-493.4%-30.1%-22.2%-16.5%-8.9%
EPS (Basic)(3.13)(0.95)(0.89)(1.02)(0.53)
EPS (Diluted)(3.00)(0.95)(0.89)(1.02)(0.53)
Weighted Avg Shares42.49M45.71M48.89M49.99M50.35M
Weighted Avg Shares (Diluted)43.86M45.71M48.89M49.99M50.35M

Immunocore Holdings plc

NASDAQ:IMCR

Intrinsic Alpha fair value

Locked

Current Price

$27.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.